-- Shareholders of Hunter-Fleming hold 3.1% stake in Newron --
Milan, Italy – May 14, 2008 - Newron Pharmaceuticals S.p.A. (“Newron”, SWX: NWRN), a research and development company focused on novel CNS and pain therapies, today announced that it has completed the acquisition of Hunter-Fleming Ltd., a private UK bio-pharmaceutical company developing new medicines to treat neurodegenerative and inflammatory disorders. As announced earlier, shareholders of Hunter-Fleming now hold 3.1 % in Newron.
About Newron Pharmaceuticals Newron Pharmaceuticals S.p.A. (www.newron.com) is a biopharmaceutical company focused on novel therapies for diseases of the Central Nervous System and pain. Newron is undertaking phase III trials with safinamide for the treatment of Parkinson’s disease (PD) in conjunction with its partner, Merck Serono, which has exclusive worldwide rights to develop, manufacture and commercialize the compound in PD, Alzheimer´s disease, and other therapeutic applications. Newron recently reported excellent results for its compound ralfinamide in patients with Nerve Compression and Entrapment conditions, where neuropathic low back pain (NLBP) represents the most common indication and for which there are no approved drugs. The company expects to commence a phase IIb/III in NLBP later in 2008. In May 2008, Newron closed the acquisition of Hunter-Fleming, a private UK bio-pharmaceutical company developing new medicines to treat neurodegenerative and inflammatory disorders. Newron is headquartered in Bresso, near Milan, Italy. The company is listed at SWX Swiss Exchange, trading symbol NWRN.
For more information, contact: Media Investors and analysts Italy Luca Benatti - CEO Phone: +39 02 6103 4 626 E-mail: pr@newron.com UK/Global media Julia Phillips Financial Dynamics Phone: +44 (0) 20 7269 7187 Switzerland Martin Meier-Pfister The Investor Relations Firm AG Phone: +41 43 244 81 40
